APOL1 and nephropathy progression in populations of african ancestry

Seminars in Nephrology

Volumn 33, Issue 5, 2013, Pages 425-432

  Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

African American; APOL1; FSGS; HIV; Kidney disease; Progression

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; CYCLOSPORIN; DEXAMETHASONE; MYCOPHENOLIC ACID; STEROID; UNCLASSIFIED DRUG;

APOLIPOPROTEIN L1 GENE; ARTICLE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FOCAL GLOMERULOSCLEROSIS; GENE; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HIV ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INHERITANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR PATHOLOGY; NEGRO; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SICKLE CELL ANEMIA;

AFRICAN AMERICAN; APOL1; FSGS; HIV; KIDNEY DISEASE; PROGRESSION;

AFRICAN AMERICANS; AIDS-ASSOCIATED NEPHROPATHY; APOLIPOPROTEINS; DISEASE PROGRESSION; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; LUPUS NEPHRITIS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS;

EID: 84885227297     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.07.004     Document Type: Article

References (60)

1. Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., Freedman B.I., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
2. Tzur S., Rosset S., Shemer R., Yudkovsky G., Selig S., Tarekegn A., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010, 128:345-350.
3. Freedman B.I., Kopp J.B., Langefeld C.D., Genovese G., Friedman D.J., Nelson G.W., et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010, 21:1422-1426.
4. O'Seaghdha C.M., Parekh R.S., Hwang S.J., Li M., Kottgen A., Coresh J., et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011, 20:2450-2456.
5. Cooke J.N., Bostrom M.A., Hicks P.J., Ng M.C., Hellwege J.N., Comeau M.E., et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2012, 27:1505-1511.
6. Kopp J.B., Smith M.W., Nelson G.W., Johnson R.C., Freedman B.I., Bowden D.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
7. Kao W.H., Klag M.J., Meoni L.A., Reich D., Berthier-Schaad Y., Li M., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185-1192.
8. Freedman B.I., Langefeld C.D., Turner J., Nunez M., High K.P., Spainhour M., et al. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 2012, 82:805-811.
9. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., An P., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011, 22:2129-2137.
10. Pattaro C., Aulchenko Y.S., Isaacs A., Vitart V., Hayward C., Franklin C.S., et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int 2009, 76:297-306.
11. Cheng W., Zhou X., Zhu L., Shi S., Lv J., Liu L., et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. Nephrol Dial Transplant 2011, 26:2544-2549.
12. US Renal Data System. US Renal Data System, USRDS 2011 annual data report: atlas of end-stage renal disease in the United States 2011, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
13. Zarif L., Covic A., Iyengar S., Sehgal A.R., Sedor J.R., Schelling J.R. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000, 15:1801-1807.
14. Freedman B.I., Bowden D.W., Rich S.S. Genetic basis of kidney disease. Brenner & Rector's the kidney 2012, 1554-1569. Elsevier Saunders, Philadelphia. 9th ed. M.W. Taal (Ed.).
15. Freedman B.I., Hicks P.J., Bostrom M.A., Cunningham M.E., Liu Y., Divers J., et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009, 75:736-745.
16. Freedman B.I., Langefeld C.D. The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant 2012, 27:1288-1291.
17. Lipkowitz M.S., Freedman B.I., Langefeld C.D., Comeau M.E., Bowden D.W., Kao W.H., et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013, 83:114-120.
18. Appel L.J., Wright J.T., Greene T., Kusek J.W., Lewis J.B., Wang X., et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008, 168:832-839. African American Study of Kidney Disease and Hypertension Collaborative Research Group.
19. Wright J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
20. Appel L.J., Anderson C.A. Compelling evidence for public health action to reduce salt intake. N Engl J Med 2010, 362:650-652.
21. Freedman B.I., Murea M. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep 2012, 14:21-28.
22. Fogo A., Breyer J.A., Smith M.C., Cleveland W.H., Agodoa L., Kirk K.A., et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) trial. AASK Pilot Study Investigators. Kidney Int 1997, 51:244-252.
23. Freedman B.I., Langefeld C.D., Murea M., Ma L., Otvos J.D., Turner J., et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant 2011, 26:3805-3810.
24. Cravedi P., Ruggenenti P., Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012, 8:301-306.
25. Abbott K.C., Hypolite I., Welch P.G., Agodoa L.Y. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001, 14:377-383.
26. Rao T.K., Filippone E.J., Nicastri A.D., Landesman S.H., Frank E., Chen C.K., et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984, 310:669-673.
27. Bourgoignie J.J. Acquired immunodeficiency syndrome (AIDS)--related renal disease. Klin Wochenschr 1989, 67:889-894.
28. Behar D.M., Shlush L.I., Maor C., Lorber M., Skorecki K. Absence of HIV-associated nephropathy in Ethiopians. Am J Kidney Dis 2006, 47:88-94.
29. Behar D.M., Kedem E., Rosset S., Haileselassie Y., Tzur S., Kra-Oz Z., et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 2011, 34:452-459.
30. Fine D.M., Wasser W.G., Estrella M.M., Atta M.G., Kuperman M., Shemer R., et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 2012, 23:343-350.
31. Ashley-Koch A.E., Okocha E.C., Garrett M.E., Soldano K., De Castro L.M., Jonassaint J.C., et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011, 155:386-394.
32. Hicks P.J., Langefeld C.D., Lu L., Bleyer A.J., Divers J., Nachman P.H., et al. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. Kidney Int 2011, 80:1339-1343.
33. Freedman B.I., Edberg J.C., Comeau M.E., Murea M., Bowden D.W., Divers J., et al. The non-muscle myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol 2010, 32:66-72.
34. Lin C.P., Adrianto I., Lessard C.J., Kelly J.A., Kaufman K.M., Guthridge J.M., et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 2012, 13:232-238.
35. Freedman B.I., Langefeld C.D., Comeau M.E., Hebert L., Segal M.S., Edberg J.C., et al. Apolipoprotein L1 risk variants associate with lupus nephritis-induced end-stage renal disease in African Americans [abstract]. J Am Soc Nephrol 2012, 23:248A.
36. McClellan W., Warnock D.G., McClure L., Campbell R.C., Newsome B.B., Howard V., et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 2006, 17:1710-1715.
37. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011, 22:2098-2105.
38. Shriner D., Herbert A., Doumatey A.P., Zhou J., Huang H., Erdos M.R., et al. Multiple loci associated with renal function in African Americans. PLoS One 2012, 7:e45112.
39. Reeves-Daniel A.M., Depalma J.A., Bleyer A.J., Rocco M.V., Murea M., Adams P.L., et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011, 11:1025-1030.
40. Moore J., McKnight A.J., Simmonds M.J., Courtney A.E., Hanvesakul R., Brand O.J., et al. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 2010, 303:1282-1287.
41. Moore J., McKnight A.J., Dohler B., Simmonds M.J., Courtney A.E., Brand O.J., et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol 2012, 23:1891-1899.
42. Lee B.T., Kumar V., Williams T.A., Abdi R., Bernhardy A., Dyer C., et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012, 12:1924-1928.
43. Cohen D.M., Mittalhenkle A., Scott D.L., Young C.J., Norman D.J. African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation 2011, 92:722-725.
44. Lentine K.L., Schnitzler M.A., Xiao H., Saab G., Salvalaggio P.R., Axelrod D., et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010, 363:724-732.
45. Gaston R.S., Young C.J. Living donor nephrectomy: understanding long-term risk in minority populations. Am J Transplant 2010, 10:2574-2576.
46. Bostrom M.A., Freedman B.I. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 2010, 5:1107-1113.
47. Atta M.G., Estrella M.M., Kuperman M., Foy M.C., Fine D.M., Racusen L.C., et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012, 82:338-343.
48. Hays T., Wyatt C.M. APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle. Kidney Int 2012, 82:259-260.
49. Bostrom M.A., Kao W.H., Li M., Abboud H.E., Adler S.G., Iyengar S.K., et al. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy. Am J Kidney Dis 2012, 59:210-221.
50. Divers J., Nunez M., High K.P., Murea M., Rocco M.V., Ma L., et al. JC Polyoma virus interacts with APOL1 in African Americans with non-diabetic nephropathy. Kidney Int 2013 May 15, [Epub ahead of print]. 10.1038/ki.2013.173.
51. Madhavan S.M., O'Toole J.F., Konieczkowski M., Ganesan S., Bruggeman L.A., Sedor J.R. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011, 22:2119-2128.
52. O'Toole J.F., Madhavan S.M., Konieczkowski M., Ganesan S., Barisoni L., Thomas D.B., et al. apol1 expression and localization pattern in kidney diseases with and without association to risk genotype [abstract]. J Am Soc Nephrol 2012, 23:323A.
53. Wakashin H., Kopp J.B. ApolipoproteinL1-B splice variant is expressed by podocytes in vitro and in vivo and shows both nuclear and cytoplasmic distribution [abstract]. J Am Soc Nephrol 2012, 23:819A.
54. Chen Z., Freedman B.I., Graham W.D., Ross N.A., Pollak M.R., Ross M.D., et al. Dose-dependent expression of apol1 protein sensitizes cell death pathways [abstract]. J Am Soc Nephrol 2012, 23:136A.
55. Dummer P.D., Hickman A., Espositio D., Winkler C.A., Pisitkun T., Kopp J.B. Apolipoprotein-L1 kidney risk variants demonstrate differential intracellular retention and altered cell biological pathways [abstract]. J Am Soc Nephrol 2012, 23:249A.
56. Bentley A.R., Doumatey A.P., Chen G., Huang H., Zhou J., Shriner D., et al. Variation in APOL1 contributes to ancestry-level differences in HDLc-kidney function association. Int J Nephrol 2012, 2012:748984.
57. Kanji Z., Powe C.E., Wenger J.B., Huang C., Ankers E., Sullivan D.A., et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 2011, 22:2091-2097.
58. Tzur S., Rosset S., Skorecki K., Wasser W.G. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 2012, 27:1498-1505.
59. Ruf R.G., Lichtenberger A., Karle S.M., Haas J.P., Anacleto F.E., Schultheiss M., et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004, 15:722-732.
60. Kopp J.B., Zhao X., Winkler C.A., Woroniecki R.P., Radeva M., Gassman J., et al. APOL1 variant-associated FSGS is more aggressive but manifests similar response to cyclosporine and mycophenolate compared to other forms of primary FSGS [abstract]. J Am Soc Nephrol 2012, 23:41A.